Polymorphisms conferring higher affinity to IgG1 have better clinical response to rituximab in follicular lymphoma [67,68], Waldestrom ́s macroglobulinemia [69], and patients with DLBCL treated with rituximab plus CHOP (R-CHOP) [70], however, CD16a/FcγRIIIa polymorphisms do not predict clinical response in CLL [71] and patients with follicular lymphoma treated with R-CHOP [72]. Here, FCGR3A is linked to follicular lymphoma.